- NanoViricides ( NYSE: NNVC ) reported that its optimistic it can speed up the process to move drug development of NV-387-T, its monkeypox drug candidate into human clinical trials quickly.
- The active ingredient tecovirimat has already been approved by the Food and Drug Administration as a smallpox treatment.
- The company NanoViricides is optimistic that it can use preclinical data from its other drug development programs to support its application for NV-387-T.
For further details see:
NanoViricides reports monkeypox antiviral could reach clinical status rapidly